Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes

Pharmacotherapy

Volumn 23, Issue 6, 2003, Pages 802-805

  Krantz, Mori J ^a   Kutinsky, Ilana B ^a   Robertson, Alastair D ^a   Mehler, Philip S ^a  

^a DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMITRIPTYLINE; COCAINE; FLUOXETINE; LEVACETYLMETHADOL; METHADONE; NELFINAVIR; OLANZAPINE;

ADULT; AGED; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; DRUG INDICATION; DRUG MEGADOSE; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HEART REPOLARIZATION; HUMAN; HYPOKALEMIA; LINEAR REGRESSION ANALYSIS; MALE; METHADONE TREATMENT; OPIATE ADDICTION; OUTPATIENT CARE; PREDICTION; QT INTERVAL; RETROSPECTIVE STUDY; TORSADE DES POINTES;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPOKALEMIA; LONG QT SYNDROME; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PAIN; RETROSPECTIVE STUDIES; TORSADES DE POINTES;

EID: 0037674750     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.6.802.32186     Document Type: Article

References (16)

1. Anonymous. Index of safety-related drug labeling change summaries approved by FDA Center for Drug Evaluation and Research (CDER). Washington, DC: Food and Drug Administration, March 2001. Available from http://www.fda.gov/medwatch/SAFETY/2001/mar01.htm#orlaam. Accessed October 25, 2002.
2. Krantz MJ, Lewkowiez L, Hays H, Woodroffe M, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-4.
3. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7:353-70.
4. Dessertenne F. Ventricular tachycardia with two variable opposing foci. Arch Mal Coeur Vaiss 1966;59:263-72.
5. Katchman AN, McGroary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther 2002;303:688-94.
6. Vincent MG. Long QT syndrome. Cardiology Clin 2000;18:309-25.
7. Maxwell S, Shinderman MS. Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone. J Addict Dis 2002;21:1-12.
8. Hays H, Woodroffe MA. Use of methadone in treating chronic noncancer pain. Pain Res Manage 1999;4:23-7.
9. Viskin S. Long QT syndromes and torsades de pointes. Lancet 1999;354:1625-33.
10. Wolbrette D, Naccarelli G, Curtis A, Lehmann M, Kadish A. Gender differences in arrhythmias. Clin Cardiol 2002;25:49-56.
11. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
12. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996;36:233-52.
13. Deamer RL, Wilson DR, Clark DS, Prichard JG. Torsades de pointes associated with high-dose levomethadyl acetate (Orlaam). J Addict Dis 2001;20:7-14.
14. European Agency for the Evaluation of Medicinal Products. EMEA public statement to suspend the marketing authorization for Orlaam (levacetylmethadol) in the European Union: April 19, 2001. London, UK: EMEA/8776/01. Available from http://www.emea.eu.int/. Accessed October 25, 2002.
15. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 2002;89:1316-19.
16. U.S. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration (SAMHSA). Available from http://www.samhsa.gov/. Accessed March 15, 2003.